Itraconazole therapy for nonmeningeal coccidioidomycosis: Clinical and laboratory observations

Richard M. Tucker, David W. Denning, Eduardo G. Arathoon, Michael G. Rinaldi, David A. Stevens

Research output: Contribution to journalArticlepeer-review

71 Scopus citations


Itraconazole, a new oral triazole antifungal agent, was administered in 75 courses to patients with chronic coccidioidomycosis at dosages of 50 to 400 mg/day for a median duration of 10 months. Assessment of efficacy was made with a standardized scoring system. Responses were seen in 42 of 58 assessable courses (72%). Nonresponse occurred exclusively in patients who had failed previous therapy and was most common in pulmonary disease. Toxicity was minimal at the doses studied. Pharmacokinetic analysis of itraconazole in serum at steady state showed negligible circadian variation; differences in serum concentrations among patients were large. Clinical isolates of Coccidioides immitis showed uniform in vitro susceptibility to itraconazole. Itraconazole shows impressive activity in this series of patients with refractory coccidioidomycosis. Further evaluation of itraconazole in this and in other systemic mycoses is in order.

Original languageEnglish (US)
Pages (from-to)593-601
Number of pages9
JournalJournal of the American Academy of Dermatology
Issue number3
StatePublished - 1990
Externally publishedYes

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Itraconazole therapy for nonmeningeal coccidioidomycosis: Clinical and laboratory observations'. Together they form a unique fingerprint.

Cite this